Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Public ClinicalTrials.gov record NCT04643002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
Study identification
- NCT ID
- NCT04643002
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 258 participants
Conditions and interventions
Conditions
Interventions
- Isatuximab Drug
- Dexamethasone Drug
- Pomalidomide Drug
- Belantamab mafodotin Drug
- Pegenzileukin Drug
- SAR439459 Drug
- Belumosudil Drug
- Evorpacept Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 25, 2021 (Actual)
- Primary completion
- Sep 13, 2027 (Estimated)
- Completion
- Apr 20, 2028 (Estimated)
- Last update posted
- Oct 13, 2026
2021 – 2028
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Winship Cancer Institute of Emory University- Site Number : 8400010 | Atlanta | Georgia | 30322 | Recruiting |
| University of Illinois-Chicago - College of Medicine- Site Number : 8400007 | Chicago | Illinois | 60612 | Completed |
| University of Michigan Health System - Ann Arbor- Site Number : 8400004 | Ann Arbor | Michigan | 48109 | Recruiting |
| Roswell Park Cancer Institute- Site Number : 8400008 | Buffalo | New York | 14263 | Recruiting |
| The Ohio State University- Site Number : 8400012 | Columbus | Ohio | 43210 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04643002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04643002 live on ClinicalTrials.gov.